+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Diagnostics Market by Product, Technology, Test Type, End User, Application - Global Forecast to 2030- Product Image
Tuberculosis Diagnostics Market by Product, Technology, Test Type, End User, Application - Global Forecast to 2030- Product Image
Sale

Tuberculosis Diagnostics Market by Product, Technology, Test Type, End User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4985929
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tuberculosis Diagnostics Market grew from USD 3.17 billion in 2024 to USD 3.35 billion in 2025. It is expected to continue growing at a CAGR of 5.51%, reaching USD 4.38 billion by 2030.

Setting the Stage for Innovations in Tuberculosis Diagnostics

The global fight against tuberculosis hinges on an ecosystem of precise, timely, and accessible diagnostic solutions. As public health initiatives strive to curb the burden of TB, diagnostic laboratories and point-of-care settings face mounting pressure to adopt tools that combine speed with accuracy. Recent advances in molecular technologies, coupled with renewed funding commitments, have injected fresh momentum into an industry poised for transformative growth.

Against this backdrop, stakeholders require a clear understanding of market drivers, regulatory influences, and technological trajectories. Decision-makers in healthcare institutions and diagnostic firms must navigate a complex matrix of supply chain dynamics, evolving reimbursement landscapes, and shifting epidemiological trends. By synthesizing these factors into a cohesive narrative, this overview lays the groundwork for strategic planning, investment prioritization, and product innovation in the years ahead.

Shifts Redefining Tuberculosis Diagnostic Ecosystems

The tuberculosis diagnostics landscape is undergoing fundamental transformations driven by breakthroughs in molecular assays, the proliferation of digital health platforms, and a reorientation of public health strategies. Cutting-edge genotypic assays and nucleic acid amplification tests now deliver rapid, high-fidelity detection of Mycobacterium tuberculosis, enabling clinicians to initiate targeted therapies within hours rather than days. Simultaneously, advances in immunological assays and imaging systems are enhancing the sensitivity and specificity of point-of-care diagnostics, addressing access gaps in resource-constrained settings.

Data analytics and artificial intelligence are further reshaping laboratory workflows, automating image interpretation for smear microscopy and streamlining sample triage. These innovations are complemented by integrated reagent-instrument ecosystems that improve throughput and reduce operational costs. On the policy front, renewed global funding commitments and streamlined regulatory pathways are accelerating product approvals, while public-private partnerships foster collaborative R&D. Together, these shifts are redefining expectations for tuberculosis diagnostics, setting new benchmarks for speed, accuracy, and scalability.

Unpacking the 2025 Tariff Wave on US Diagnostics Supply Chains

The introduction of new United States tariffs in 2025 has rippled across the global tuberculosis diagnostics supply chain, elevating costs for both consumables and instrumentation. Import duties on kits, reagents, culture systems, microscopy units, and PCR machines have prompted many manufacturers to reevaluate their sourcing strategies. The direct impact has manifested in higher price tags for end users and lengthened procurement cycles as buyers negotiate new contracts and seek alternative suppliers.

This tariff wave has also galvanized efforts to localize manufacturing in key markets, with several stakeholders forging partnerships to establish regional production hubs. While such investments promise long-term resilience, they require substantial upfront capital and regulatory alignment. In parallel, distributors and diagnostic service providers are recalibrating their price models, balancing margin pressures against the imperative to maintain testing volumes. As cost dynamics continue to evolve, market participants must remain agile, leveraging strategic collaborations and supply chain diversification to mitigate tariff-driven disruptions.

Dissecting Market Segmentation to Illuminate Growth Drivers

Analyzing the market through multiple segmentation lenses reveals nuanced growth pockets and emerging challenges. By product category, consumables such as test kits and reagents continue to dominate testing volumes, while instruments spanning culture systems, microscopy platforms, and both conventional and real-time PCR machines drive capital expenditures. The interplay between reagent supply and instrument utilization underscores the need for integrated solutions that optimize throughput and minimize downtime.

From a technological perspective, molecular assays split into genotypic tests and advanced amplification techniques-encompassing both isothermal methods like LAMP and PCR-based platforms-are capturing an increasing share of diagnostic workflows. Nonmolecular approaches, including imaging systems and immunoassays, retain critical roles in initial screening and resource-limited environments. Test types further delineate this landscape: detection assays ranging from blood-based tests and smear microscopy to culture-based and molecular methods address early diagnosis needs, while drug susceptibility testing leverages molecular DST and phenotypic approaches to guide therapy.

End users reflect diverse operational requirements, with clinics demanding rapid, point-of-care formats, hospitals prioritizing high-throughput laboratory instruments, and reference laboratories investing in comprehensive systems. Application segments bifurcate into active tuberculosis diagnostics-spanning pulmonary and extrapulmonary testing-and latent TB screening, each necessitating distinct assay sensitivities and workflow integrations.

Regional Dynamics Shaping Global Tuberculosis Testing Trends

Geographic dynamics play a pivotal role in shaping demand and deployment strategies across regions. In the Americas, robust reimbursement frameworks and established laboratory networks have accelerated adoption of sophisticated molecular platforms, though Latin American markets often contend with budget constraints and fragmented procurement processes. Across Europe, regulatory harmonization under the In Vitro Diagnostic Regulation streamlines approvals for novel assays, while targeted investments in the Middle East bolster capacity in private and public healthcare settings. Sub-Saharan Africa, facing some of the highest TB burdens, continues to rely heavily on donor-funded initiatives and NGOs, though localized manufacturing projects show promise in enhancing supply stability.

Within the Asia-Pacific region, high disease prevalence in countries such as India and China has spurred government-led screening campaigns and public health collaborations. Rapidly expanding laboratory infrastructure and growing private sector engagement underpin a surge in demand for both cost-effective rapid tests and fully automated molecular systems. Southeast Asian markets, meanwhile, present opportunities for portable, low-power devices that cater to rural outreach programs. Together, these regional insights guide strategic deployment of resources, ensuring solutions align with local epidemiology and healthcare delivery models.

Competitive Landscape and Strategic Positioning of Leading Diagnostics Firms

Leading players in the tuberculosis diagnostics arena are executing multifaceted strategies to consolidate market share and broaden their technological portfolios. Global diagnostics giants have pursued targeted acquisitions of niche molecular assay developers to bolster their R&D pipelines, while forging distribution alliances to penetrate underserved markets. Simultaneously, specialized biotechnology firms are innovating in areas such as rapid molecular detection, point-of-care immunoassays, and AI-driven image analysis, differentiating their offerings through speed and ease of use.

Strategic partnerships between reagent suppliers and instrument manufacturers have emerged as a critical avenue for creating end-to-end diagnostic ecosystems, reducing integration barriers for laboratory customers. Investment in emerging markets remains a priority, with companies customizing pricing models and financing plans to meet diverse healthcare budgets. Moreover, sustained focus on regulatory compliance and quality management systems ensures that product approvals and post-market surveillance adhere to evolving international standards. Collectively, these competitive maneuvers define a landscape characterized by both consolidation and innovation.

Strategic Imperatives for Stakeholders to Capitalize on Emerging Opportunities

To navigate this dynamic environment, industry leaders should prioritize development of modular diagnostic platforms that integrate seamlessly with existing laboratory workflows and digital health infrastructures. Diversifying manufacturing bases and engaging local partners will mitigate tariff-related risks while shortening supply chains. Companies must also invest in scalable reagent-instrument bundles that support both high-volume central labs and decentralized point-of-care sites, enabling flexible deployment based on regional needs.

Strengthening collaborations with public health agencies and NGOs can catalyze product validation in real-world settings, accelerating adoption and generating critical performance data. Tailoring pricing strategies to accommodate tiered markets-ranging from high-income regions to resource-constrained areas-will broaden market penetration. Additionally, leveraging data analytics and AI for predictive maintenance and quality assurance can reduce operational inefficiencies and enhance customer value. By aligning product innovation with strategic partnerships and adaptive business models, stakeholders can secure sustainable growth and deliver greater impact in the fight against tuberculosis.

Robust Methodological Framework Underpinning Market Insights

This analysis draws on a rigorous research framework combining primary and secondary data sources. In-depth interviews with laboratory directors, procurement specialists, and public health policymakers provided qualitative insights into operational challenges, adoption barriers, and regulatory expectations. Complementing these conversations, a comprehensive review of peer-reviewed journals, government publications, and industry white papers ensured broad coverage of technological trends and policy developments.

Market segmentation was validated through a triangulation of sales data, installation footprints, and expert assessments, ensuring that product, technology, test-type, end-user, and application categorizations accurately reflect current practices. Regional analyses incorporated epidemiological statistics from global health databases, while company profiles integrated financial disclosures, patent filings, and strategic announcements. All data points underwent stringent quality checks, and findings were cross-examined with external subject-matter experts to uphold methodological integrity and deliver actionable, reliable insights.

Synthesizing Key Takeaways for Informed Decision-Making

In summary, the tuberculosis diagnostics market stands at an inflection point defined by technological advancements, shifting regulatory landscapes, and evolving supply chain paradigms. Molecular assays, digital health integration, and point-of-care innovations are reshaping diagnostic workflows, while fresh policy support and funding mechanisms are accelerating product adoption. At the same time, tariff-induced cost pressures and regional disparities emphasize the need for flexible manufacturing and distribution strategies.

Stakeholders equipped with a holistic understanding of market segmentation, regional nuances, and competitive dynamics are best positioned to make strategic investments and design customer-centric solutions. By translating these insights into targeted product development, collaborative partnerships, and adaptive business models, industry leaders can contribute meaningfully to global TB control efforts, ultimately advancing toward the goal of a world free from the burden of tuberculosis.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product
    • Consumables
      • Kits
      • Reagents
    • Instruments
      • Culture Systems
      • Microscopy Systems
      • Pcr Machines
        • Conventional Pcr Machines
        • Real-Time Pcr Machines
  • Technology
    • Molecular
      • Genotypic Assays
      • Nucleic Acid Amplification Tests
        • Lamp
        • Pcr-Based
    • Nonmolecular
      • Imaging
      • Immunological Assays
  • Test Type
    • Detection Test
      • Blood Tests
      • Culture-Based Tests
      • Molecular Tests
      • Skin Tests
      • Smear Microscopy
    • Drug Susceptibility Testing
      • Molecular Dst
      • Phenotypic Dst
  • End User
    • Clinics
    • Hospitals
    • Reference Laboratories
  • Application
    • Active Tb
      • Extrapulmonary Tb
      • Pulmonary Tb
    • Latent Tb
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Cepheid, Inc.
  • Becton, Dickinson and Company
  • Hain Lifescience GmbH
  • Molbio Diagnostics Private Limited
  • bioMérieux SA
  • Abbott Molecular Inc.
  • Thermo Fisher Scientific Inc.
  • Roche Diagnostics International AG
  • QIAGEN N.V.
  • Hologic, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tuberculosis Diagnostics Market, by Product
8.1. Introduction
8.2. Consumables
8.2.1. Kits
8.2.2. Reagents
8.3. Instruments
8.3.1. Culture Systems
8.3.2. Microscopy Systems
8.3.3. Pcr Machines
8.3.3.1. Conventional Pcr Machines
8.3.3.2. Real-Time Pcr Machines
9. Tuberculosis Diagnostics Market, by Technology
9.1. Introduction
9.2. Molecular
9.2.1. Genotypic Assays
9.2.2. Nucleic Acid Amplification Tests
9.2.2.1. Lamp
9.2.2.2. Pcr-Based
9.3. Nonmolecular
9.3.1. Imaging
9.3.2. Immunological Assays
10. Tuberculosis Diagnostics Market, by Test Type
10.1. Introduction
10.2. Detection Test
10.2.1. Blood Tests
10.2.2. Culture-Based Tests
10.2.3. Molecular Tests
10.2.4. Skin Tests
10.2.5. Smear Microscopy
10.3. Drug Susceptibility Testing
10.3.1. Molecular Dst
10.3.2. Phenotypic Dst
11. Tuberculosis Diagnostics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Reference Laboratories
12. Tuberculosis Diagnostics Market, by Application
12.1. Introduction
12.2. Active Tb
12.2.1. Extrapulmonary Tb
12.2.2. Pulmonary Tb
12.3. Latent Tb
13. Americas Tuberculosis Diagnostics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Tuberculosis Diagnostics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Tuberculosis Diagnostics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Cepheid, Inc.
16.3.2. Becton, Dickinson and Company
16.3.3. Hain Lifescience GmbH
16.3.4. Molbio Diagnostics Private Limited
16.3.5. bioMérieux SA
16.3.6. Abbott Molecular Inc.
16.3.7. Thermo Fisher Scientific Inc.
16.3.8. Roche Diagnostics International AG
16.3.9. QIAGEN N.V.
16.3.10. Hologic, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TUBERCULOSIS DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. TUBERCULOSIS DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. TUBERCULOSIS DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MICROSCOPY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LAMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 85. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 86. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 87. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 89. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 90. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 91. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 93. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 94. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 97. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 101. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 103. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 105. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 107. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 108. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 168. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 169. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 170. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 172. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 174. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 175. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 176. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 178. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 179. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 182. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 184. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 186. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 188. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 190. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 191. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 192. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 193. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 210. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 211. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 212. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 213. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 214. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 215. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 216. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 217. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 218. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 219. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 220. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 221. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 224. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 225. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 226. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 227. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 228. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 230. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 231. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 232. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 233. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 234. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 235. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 280. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 281. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 282. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 283. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 284. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 286. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 287. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 288. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 289. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 290. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 291. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 308. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 309. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 310. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 311. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, 2018-2030 (USD MILLION)
TABLE 312. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 313. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 314. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2030 (USD MILLION)
TABLE 315. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2030 (USD MILLION)
TABLE 316. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 317. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2030 (USD MILLION)
TABLE 318. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2030 (USD MILLION)
TABLE 319. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2030 (USD MILLION)
TABLE 322. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 323. FI

Companies Mentioned

The companies profiled in this Tuberculosis Diagnostics market report include:
  • Cepheid, Inc.
  • Becton, Dickinson and Company
  • Hain Lifescience GmbH
  • Molbio Diagnostics Private Limited
  • bioMérieux SA
  • Abbott Molecular Inc.
  • Thermo Fisher Scientific Inc.
  • Roche Diagnostics International AG
  • QIAGEN N.V.
  • Hologic, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.35 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.38 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Tuberculosis Testing Market by Test Type, End User, Technology, Sample Type, Distribution Channel, Application - Global Forecast to 2030 - Product Image

Tuberculosis Testing Market by Test Type, End User, Technology, Sample Type, Distribution Channel, Application - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Type (Detection Of Latent Infection, Phage Assay, Nucleic Acid Testing), By End-use (Diagnostic Laboratories, Hospitals & Clinic), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Type (Detection Of Latent Infection, Phage Assay, Nucleic Acid Testing), By End-use (Diagnostic Laboratories, Hospitals & Clinic), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Tuberculosis Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Tuberculosis Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand (QFT-Plus), Test Type, Application, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand (QFT-Plus), Test Type, Application, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Tuberculosis Diagnostics Market Report by Disease Stage, Test Type, End-User, and Region 2024-2032 - Product Image

Tuberculosis Diagnostics Market Report by Disease Stage, Test Type, End-User, and Region 2024-2032

  • Report
  • 147 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.